Related Experiment Video

Updated: Jan 20, 2026

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
07:31

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs

Published on: May 24, 2016

18.2K

The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma

Hao Chen1, Meng Yang2, Qinghua Wang1

  • 1Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Oncoimmunology
|August 16, 2019
PubMed

Insights

Predicting response to immune checkpoint blockade (ICB) in melanoma is crucial. This study identifies new gene mutations and a T>C mutation signature associated with ICB resistance, while high neoantigen quality predicts longer survival.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Immune checkpoint blockade (ICB) therapy, including CTLA-4 and PD-1 inhibitors, offers significant clinical benefits for melanoma patients.
  • Predictive biomarkers for ICB response in melanoma remain incompletely understood, necessitating further investigation.

Purpose of the Study:

  • To systematically analyze the association between somatic mutation profiles and clinicopathologic information in melanoma patients treated with ICB.
  • To identify novel biomarkers that predict response and survival outcomes in melanoma patients undergoing ICB therapy.

Main Methods:

  • Analysis of somatic mutation profiles and clinicopathologic data from 336 melanoma patients treated with ICB (CTLA-4/PD-1).
  • Identification of significantly mutated genes using statistical association.
  • Evaluation of mutational signatures and neoantigen quality in relation to treatment response and survival using logistic regression, log-rank tests, and Cox proportional hazards models.

Main Results:

  • Eight novel significantly mutated genes (COL5A1, SEMA3E, COL28A1, DGKG, RAPGEF5, GLDN, NCF2, and RCAN2) were identified.
  • A mutational signature characterized by T>C mutations was associated with immune resistance (OR, 2.59; P = .043).
  • High neoantigen quality correlated with prolonged immunotherapy survival (P = .009), a finding robust after controlling for covariates (HR, 0.56; P = .003).

Conclusions:

  • The study provides new insights into potential biomarkers for predicting ICB treatment benefit in melanoma.
  • Identified gene mutations and neoantigen quality represent promising avenues for future biomarker development.
  • Further validation studies are required to confirm the clinical utility of these biomarkers for melanoma patients.
Keywords:
COL5A1Melanomaimmunotherapymutational signaturesneoantigen quality

More Related Videos

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.8K
A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.1K

Related Concept Videos

Neuromuscular Junction And Blockade01:29

Neuromuscular Junction And Blockade

The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
4.8K
Protein Folding Quality Check in the RER01:29

Protein Folding Quality Check in the RER

ER is the primary site for the maturation and folding of soluble and transmembrane secretory proteins. The calnexin cycle is a specific chaperone system that folds and assesses the confirmation of N-glycosylated proteins before they can exit the ER lumen. The primary players of this quality check pipeline are the lectins, ER-resident chaperones, and a glucosyl transferase enzyme. In case the calnexin system in the lumen fails to salvage a misfolded protein, it is transported to the cytoplasm...
5.0K
What is the Immune System?01:38

What is the Immune System?

Overview
127.0K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.4K
Humoral Immune Responses01:36

Humoral Immune Responses

Overview
83.4K
Group Therapy01:26

Group Therapy

Group therapy is a sociocultural approach to psychological treatment, where individuals with shared psychological challenges come together under the guidance of a mental health professional. This therapeutic modality offers unique opportunities for individuals to connect, share, and grow within the context of a supportive group. By fostering mutual understanding and collaboration, group therapy can address a range of psychological concerns effectively, often complementing or surpassing the...
374